Fiche personne


Territoire

Alsace

Statut

Hospitalo-Universitaire

Publications


Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?

Vukusic S, Hubben F, Gavoille A, Malek Y, Casez O, Kremer L, Palpacuer T, Marignier R, Durand-Dubief F, Androdias-Condemine G, Pique J, Maillart E, Vermersch P, de Seze J

Mult Scler. 2025 06;31(7):877-881

Comorbidities Are Associated With Unfavorable Outcome in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Exploratory Study From the CROCTINO Cohort.

Samadzadeh S, Oertel FC, Salih H, Lin TY, Motamedi S, Chien C, Cook LJ, Lana-Peixoto MA, Fontenelle MA, Kim HJ, Hyun JW, Jung SK, Palace J, Roca-Fernandez A, Leite MI, Sharma SM, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, Dcunha A, Aktas O, Ringelstein M, Albrecht P, May EF, Tongco C, Leocani L, Pisa M, Radaelli M, Sánchez-Dalmau B, Martinez-Lapiscina EH, Stiebel-Kalish H, Hellmann MA, Lotan I, Siritho S, de Seze J, Senger T, Havla J, Marignier R, Tilikete CF, Cobo-Calvo A, Bichuetti D, Tavares IM, Soelberg K, Altintas A, Yildirim R, Tanriverdi U, Jacob A, Huda S, Rimler Z, Reid A, Mao-Draayer Y, Villoslada P, de Castillo IS, Green A, Petzold A, Yeaman MR, Smith TJ, Brandt AU, Zimmermann HG, Paul F, Asgari N,

Eur J Neurol. 2025 06;32(6):e70214

An update on the evaluation of treatment switching criteria in multiple sclerosis.

Bigaut K, Didierjean J, de Seze J

Expert Rev Neurother. 2025 05 13;:

Voir plus